Runben Biotechnology Co

Runben Biotechnology Co Financial Leverage

The Financial Leverage (Equity Multiplier) of Runben Biotechnology Co (603193.SS) as of Oct 21, 2026 is 1.05. In the previous year, Financial Leverage (Equity Multiplier) was 1.07 — a change of -1.33% (lower).

Financial Leverage

1.05

YoY

-1.33%

Last updated:

Financial Leverage (Equity Multiplier) of Runben Biotechnology Co is 2025 1.05 . Financial Leverage (Equity Multiplier) of Runben Biotechnology Co was 2024 1.07 . It decreases by -1.33% lower compared to the previous year.

The Runben Biotechnology Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.20 CNY
Jan 1, 2020
1.11 CNY
Jan 1, 2021
1.15 CNY
Jan 1, 2022
1.14 CNY
Jan 1, 2023
1.05 CNY
Jan 1, 2024
1.07 CNY
Jan 1, 2025
1.05 CNY
The Runben Biotechnology Co Financial Leverage history
YEARFinancial LeverageYoY
1.05-1.33%
1.07+1.52%
1.05-8.01%
1.14-0.74%
1.15+4.12%
1.11-7.67%
1.20—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Runben Biotechnology Co Stock analysis

What does Runben Biotechnology Co do? Runben Biotechnology Co., Ltd. generates revenue through the research, development, manufacture, and sale of mosquito repellent, baby care, and personal care products. The company's main product categories include electric mosquito repellent liquid, DEET mosquito repellent liquid, lipstick, face cream, facial cleanser, and skin care cream, which are sold via online direct sales, online platform distribution, and online platform agency sales. These products target domestic consumers in China, with the firm focusing on internet-based sales channels to reach its customer base. The company's product portfolio spans mosquito repellent solutions, baby care items, and essential oil products, with key offerings such as DEET mosquito repellent liquid and electric mosquito repellent liquid driving sales. Baby care products and personal care items like lipstick and face cream are distributed through online platforms, leveraging digital channels to serve the domestic market. Runben Biotechnology emphasizes direct consumer engagement through e-commerce platforms to facilitate product distribution. Runben Biotechnology's revenue streams are derived from the sale of its core product lines, including mosquito repellent products, baby care products, and essential oil products. The firm's domestic market focus ensures that its products, such as facial cleanser and skin care cream, are tailored to local consumer preferences. Online sales models, including direct online sales and platform agency sales, form the primary channel for product delivery to end-users. Runben Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Runben Biotechnology Co stock

Financial Leverage (Equity Multiplier) of Runben Biotechnology Co is 1.05 in 2025.

Financial Leverage (Equity Multiplier) of Runben Biotechnology Co changed from 1.07 to 1.05, representing a -1.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Runben Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Runben Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Runben Biotechnology Co

All Key Metrics — Runben Biotechnology Co